Rob Dillard

GI Oncology Now

Pancreatic ductal adenocarcinoma is one of the most aggressive forms of pancreatic cancer, with a 5-year survival rate of less than 10%. Results from a recent study <a href="https://www.nature.com/articles/s43018-023-00614-y" target="_blank" rel="noopener">published</a> in Nature Cancer suggest a novel therapy that targets scar-like fibrotic tissue in tumors may be an effective treatment.The drug, PXS-5505, increased survival more than 35% compared with chemotherapy treatment alone when used in mouse models. &ldquo;The preclinical validation of&nbsp;this first-in-class, antifibrotic drug marks a major milestone in our quest to overcome the significant challenges in treating pancreatic cancer and brings hope to patients and their families,&rdquo; said Thomas Cox, an associate professor, head of the&nbsp;Matrix&nbsp;and&nbsp;Metastasis Lab&nbsp;at the Garvan Institute of Medical Research, and senior author of the study, in a <a href="https://www.eurekalert.org/news-releases/999915" target="_blank" rel="noopener">press release.</a>PXS-5505 works by blocking enzymes that play a critical role in depositing collagen into the fibrotic tissue around tumors. It was developed by the Sydney, Australia-based pharmaceutical research company Pharmaxis and is currently in phase 2 clinical trials for the treatment of bone marrow cancer.Working in concert with Pharmaxis, Garvan researchers found that PXS-5505 not only reduced fibrosis in pancreatic tumors, but also reduced the spread of cancer to other organs, such as the liver, by 45%.&ldquo;PXS-5505 returns the&nbsp;tumor microenvironment to a more &lsquo;normal&rsquo; state&nbsp;by reducing fibrosis and&nbsp;decreasing tumor stiffness,&rdquo; Dr. Jessica Chitty, senior research officer at Garvan and first author of the study, explained. &ldquo;This allows chemotherapy drugs to penetrate the tumors more easily, work more effectively, and destroy more cancer cells.&rdquo;According to Prof. Cox, &ldquo;PXS-5505 shows real potential to improve chemotherapy for patients. We are now in the process of progressing this work toward clinical trials that will evaluate this promising drug combination approach for pancreatic cancer patients.&rdquo;

Michael Foote, MD

CheckMate 8HW: Nivolumab + Ipilimumab Shows Durable PFS Benefit in MSI-H/dMMR CRC

Colorectal Cancer

BREAKWATER Trial Signals New First-Line Option for BRAF V600E CRC

Emily Menendez

FDA Approves Cabozantinib for Advanced Pancreatic and Extrapancreatic NETs

GEP-NETs

Latest News

Novel Drug Shows Promise in Treating Aggressive Pancreatic Cancer

Pancreatic Cancer

Results from a recent study suggest a novel therapy that may effectively treat pancreatic ductal adenocarcinoma.